Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

  • receipt Report ID : 125539
  • calendar_today Published On: Oct, 2020
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

Market Overview

The Chemotherapy Induced Peripheral Neuropathy Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Chemotherapy Induced Peripheral Neuropathy Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.1%% in the forecast period of 2020 to 2025 and will expected to reach USD 1925.4 million by 2025, from USD 1520.1 million in 2019.

Market segmentation

Chemotherapy Induced Peripheral Neuropathy Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Chemotherapy Induced Peripheral Neuropathy Treatment market has been segmented into:

Calcium Channel _2-delta Ligands

Antidepressants

Opioids

Others

By Application, Chemotherapy Induced Peripheral Neuropathy Treatment has been segmented into:

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Regions and Countries Level Analysis

Regional analysis is another highly comprehensive part of the research and analysis study of the global Chemotherapy Induced Peripheral Neuropathy Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Chemotherapy Induced Peripheral Neuropathy Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Chemotherapy Induced Peripheral Neuropathy Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Chemotherapy Induced Peripheral Neuropathy Treatment market in important countries (regions), including:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Analysis

Chemotherapy Induced Peripheral Neuropathy Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Chemotherapy Induced Peripheral Neuropathy Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Chemotherapy Induced Peripheral Neuropathy Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Chemotherapy Induced Peripheral Neuropathy Treatment are:

Aptinyx Inc

Sova Pharmaceuticals Inc

MAKScientific LLC

Asahi Kasei Pharma Corp

PledPharma

Regenacy Pharmaceuticals

Kineta Inc

Nemus Bioscience Inc

Metys Pharmaceuticals AG

DermaXon LLC

Solasia Pharma K.K.

Krenitsky Pharmaceuticals Inc

WinSanTor

PeriphaGen

Apexian Pharma

Among other players domestic and global, Chemotherapy Induced Peripheral Neuropathy Treatment market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Our analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

1.1 Product Overview and Scope of Chemotherapy Induced Peripheral Neuropathy Treatment

1.2 Classification of Chemotherapy Induced Peripheral Neuropathy Treatment by Type

1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type: 2015 VS 2019 VS 2025

1.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type in 2019

1.2.3 Calcium Channel _2-delta Ligands

1.2.4 Antidepressants

1.2.5 Opioids

1.2.6 Others

1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market by Application

1.3.1 Overview: Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application: 2015 VS 2019 VS 2025

1.3.2 Platinum Agents

1.3.3 Taxanes

1.3.4 Vinca Alkaloids

1.3.5 Others

1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market by Regions

1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Regions: 2015 VS 2019 VS 2025

1.4.2 Global Market Size of Chemotherapy Induced Peripheral Neuropathy Treatment (2015-2025)

1.4.3 North America (USA, Canada and Mexico) Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2015-2025)

1.4.4 Europe (Germany, France, UK, Russia and Italy) Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2015-2025)

1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2015-2025)

1.4.6 South America (Brazil, Argentina, Colombia) Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2015-2025)

1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2015-2025)

2 Company Profiles

2.1 Aptinyx Inc

2.1.1 Aptinyx Inc Details

2.1.2 Aptinyx Inc Major Business

2.1.3 Aptinyx Inc SWOT Analysis

2.1.4 Aptinyx Inc Product and Services

2.1.5 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.2 Sova Pharmaceuticals Inc

2.2.1 Sova Pharmaceuticals Inc Details

2.2.2 Sova Pharmaceuticals Inc Major Business

2.2.3 Sova Pharmaceuticals Inc SWOT Analysis

2.2.4 Sova Pharmaceuticals Inc Product and Services

2.2.5 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.3 MAKScientific LLC

2.3.1 MAKScientific LLC Details

2.3.2 MAKScientific LLC Major Business

2.3.3 MAKScientific LLC SWOT Analysis

2.3.4 MAKScientific LLC Product and Services

2.3.5 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.4 Asahi Kasei Pharma Corp

2.4.1 Asahi Kasei Pharma Corp Details

2.4.2 Asahi Kasei Pharma Corp Major Business

2.4.3 Asahi Kasei Pharma Corp SWOT Analysis

2.4.4 Asahi Kasei Pharma Corp Product and Services

2.4.5 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.5 PledPharma

2.5.1 PledPharma Details

2.5.2 PledPharma Major Business

2.5.3 PledPharma SWOT Analysis

2.5.4 PledPharma Product and Services

2.5.5 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.6 Regenacy Pharmaceuticals

2.6.1 Regenacy Pharmaceuticals Details

2.6.2 Regenacy Pharmaceuticals Major Business

2.6.3 Regenacy Pharmaceuticals Product and Services

2.6.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.7 Kineta Inc

2.7.1 Kineta Inc Details

2.7.2 Kineta Inc Major Business

2.7.3 Kineta Inc Product and Services

2.7.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.8 Nemus Bioscience Inc

2.8.1 Nemus Bioscience Inc Details

2.8.2 Nemus Bioscience Inc Major Business

2.8.3 Nemus Bioscience Inc Product and Services

2.8.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.9 Metys Pharmaceuticals AG

2.9.1 Metys Pharmaceuticals AG Details

2.9.2 Metys Pharmaceuticals AG Major Business

2.9.3 Metys Pharmaceuticals AG Product and Services

2.9.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.10 DermaXon LLC

2.10.1 DermaXon LLC Details

2.10.2 DermaXon LLC Major Business

2.10.3 DermaXon LLC Product and Services

2.10.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.11 Solasia Pharma K.K.

2.11.1 Solasia Pharma K.K. Details

2.11.2 Solasia Pharma K.K. Major Business

2.11.3 Solasia Pharma K.K. Product and Services

2.11.4 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.12 Krenitsky Pharmaceuticals Inc

2.12.1 Krenitsky Pharmaceuticals Inc Details

2.12.2 Krenitsky Pharmaceuticals Inc Major Business

2.12.3 Krenitsky Pharmaceuticals Inc Product and Services

2.12.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.13 WinSanTor

2.13.1 WinSanTor Details

2.13.2 WinSanTor Major Business

2.13.3 WinSanTor Product and Services

2.13.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.14 PeriphaGen

2.14.1 PeriphaGen Details

2.14.2 PeriphaGen Major Business

2.14.3 PeriphaGen Product and Services

2.14.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

2.15 Apexian Pharma

2.15.1 Apexian Pharma Details

2.15.2 Apexian Pharma Major Business

2.15.3 Apexian Pharma Product and Services

2.15.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)

3 Market Competition, by Players

3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Share by Players (2015-2020)

3.2 Market Concentration Rate

3.2.1 Top 5 Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share

3.2.2 Top 10 Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share

3.3 Market Competition Trend

4 Market Size by Regions

4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Regions

4.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

4.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

4.4 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

4.5 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

4.6 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

5 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries

5.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2015-2020)

5.2 USA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

5.3 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

5.4 Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

6 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries

6.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2015-2020)

6.2 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

6.3 UK Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

6.4 France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

6.5 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

6.6 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

7 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries

7.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2015-2020)

7.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

7.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

7.4 Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

7.5 India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

7.6 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

8 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries

8.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2015-2020)

8.2 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

8.3 Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

9 Middle East & Africa Revenue Chemotherapy Induced Peripheral Neuropathy Treatment by Countries

9.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2015-2020)

9.2 Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

9.3 UAE Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

9.4 Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

9.5 South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

10 Market Size Segment by Type

10.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Type (2015-2020)

10.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Type (2019-2024)

10.3 Calcium Channel _2-delta Ligands Revenue Growth Rate (2015-2025)

10.4 Antidepressants Revenue Growth Rate (2015-2025)

10.5 Opioids Revenue Growth Rate (2015-2025)

10.6 Others Revenue Growth Rate (2015-2025)

11 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment by Application

11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2015-2020)

11.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Application (2019-2024)

11.3 Platinum Agents Revenue Growth (2015-2020)

11.4 Taxanes Revenue Growth (2015-2020)

11.5 Vinca Alkaloids Revenue Growth (2015-2020)

11.6 Others Revenue Growth (2015-2020)

12 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast (2021-2025)

12.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast (2021-2025)

12.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Regions (2021-2025)

12.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

12.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

12.5 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

12.6 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

12.7 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

14.3 Disclaimer

14.4 About US

List of Tables

Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025

Table 2. Breakdown of Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025

Table 4. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Comparison by Regions 2015-2025

Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Growth Estimation in Various Scenarios in 2020

Table 6. Aptinyx Inc Corporate Information, Location and Competitors

Table 7. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 8. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 9. Aptinyx Inc SWOT Analysis

Table 10. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 11. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 12. Sova Pharmaceuticals Inc Corporate Information, Location and Competitors

Table 13. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 14. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2018-2019)

Table 15. Sova Pharmaceuticals Inc SWOT Analysis

Table 16. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 17. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 18. MAKScientific LLC Corporate Information, Location and Competitors

Table 19. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 20. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 21. MAKScientific LLC SWOT Analysis

Table 22. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 23. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 24. Asahi Kasei Pharma Corp Corporate Information, Location and Competitors

Table 25. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 26. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 27. Asahi Kasei Pharma Corp SWOT Analysis

Table 28. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 29. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 30. PledPharma Corporate Information, Location and Competitors

Table 31. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 32. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 33. PledPharma SWOT Analysis

Table 34. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 35. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 36. Regenacy Pharmaceuticals Corporate Information, Location and Competitors

Table 37. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 38. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 39. Regenacy Pharmaceuticals SWOT Analysis

Table 40. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 41. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 42. Kineta Inc Corporate Information, Location and Competitors

Table 43. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 44. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 45. Kineta Inc SWOT Analysis

Table 46. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 47. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 48. Nemus Bioscience Inc Corporate Information, Location and Competitors

Table 49. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 50. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 51. Nemus Bioscience Inc SWOT Analysis

Table 52. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 53. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 54. Metys Pharmaceuticals AG Corporate Information, Location and Competitors

Table 55. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 56. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 57. Metys Pharmaceuticals AG SWOT Analysis

Table 58. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 59. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 60. DermaXon LLC Corporate Information, Location and Competitors

Table 61. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 62. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 63. DermaXon LLC SWOT Analysis

Table 64. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 65. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 66. Solasia Pharma K.K. Corporate Information, Location and Competitors

Table 67. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 68. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 69. Solasia Pharma K.K. SWOT Analysis

Table 70. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 71. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 72. Krenitsky Pharmaceuticals Inc Corporate Information, Location and Competitors

Table 73. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 74. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 75. Krenitsky Pharmaceuticals Inc SWOT Analysis

Table 76. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 77. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 78. WinSanTor Corporate Information, Location and Competitors

Table 79. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 80. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 81. WinSanTor SWOT Analysis

Table 82. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 83. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 84. PeriphaGen Corporate Information, Location and Competitors

Table 85. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 86. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 87. PeriphaGen SWOT Analysis

Table 88. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 89. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 90. Apexian Pharma Corporate Information, Location and Competitors

Table 91. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Major Business

Table 92. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Total Revenue (USD Million) (2017-2018)

Table 93. Apexian Pharma SWOT Analysis

Table 94. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 95. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)

Table 96. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) by Players (2015-2020)

Table 97. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Players (2015-2020)

Table 98. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) by Regions (2015-2020)

Table 99. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions (2015-2020)

Table 100. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2015-2020)

Table 101. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020)

Table 102. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) by Countries (2015-2020)

Table 103. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) by Countries (2015-2020)

Table 104. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2015-2020)

Table 105. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020)

Table 106. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) by Countries (2015-2020)

Table 107. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020)

Table 108. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) by Type (2015-2020)

Table 109. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2015-2020)

Table 110. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2021-2025)

Table 111. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2015-2020)

Table 112. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2015-2020)

Table 113. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Application (2021-2025)

Table 114. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Forecast by Regions (2021-2025)

List of Figures

Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Picture

Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type in 2019

Figure 3. Calcium Channel _2-delta Ligands Picture

Figure 4. Antidepressants Picture

Figure 5. Opioids Picture

Figure 6. Others Picture

Figure 7. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application in 2019

Figure 8. Platinum Agents Picture

Figure 9. Taxanes Picture

Figure 10. Vinca Alkaloids Picture

Figure 11. Others Picture

Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) and Growth Rate (2015-2025)

Figure 13. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)

Figure 14. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)

Figure 15. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)

Figure 16. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)

Figure 17. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)

Figure 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)

Figure 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Players in 2019

Figure 20. Global Top 5 Players Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in 2019

Figure 21. Global Top 10 Players Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in 2019

Figure 22. Key Players Market Share Trend

Figure 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)

Figure 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions (2015-2020)

Figure 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions in 2018

Figure 26. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 27. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 28. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 29. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 30. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 31. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020)

Figure 32. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2019

Figure 33. USA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 34. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 35. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 36. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020)

Figure 37. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2019

Figure 38. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 39. UK Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 40. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 41. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 42. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 43. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020)

Figure 44. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2019

Figure 45. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 46. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 47. Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 48. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 49. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 50. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020)

Figure 51. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2019

Figure 52. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 53. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 54. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020)

Figure 55. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2019

Figure 56. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 57. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 58. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 59. South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2020)

Figure 60. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2015-2020)

Figure 61. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type in 2019

Figure 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Type (2021-2025)

Figure 63. Global Calcium Channel _2-delta Ligands Revenue Growth Rate (2015-2020)

Figure 64. Global Antidepressants Revenue Growth Rate (2015-2020)

Figure 65. Global Opioids Revenue Growth Rate (2015-2020)

Figure 66. Global Others Revenue Growth Rate (2015-2020)

Figure 67. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2015-2020)

Figure 68. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application in 2019

Figure 69. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Application (2021-2025)

Figure 70. Global Platinum Agents Revenue Growth Rate (2015-2020)

Figure 71. Global Taxanes Revenue Growth Rate (2015-2020)

Figure 72. Global Vinca Alkaloids Revenue Growth Rate (2015-2020)

Figure 73. Global Others Revenue Growth Rate (2015-2020)

Figure 74. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)

Figure 75. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Forecast by Regions (2021-2025)

Figure 76. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Regions (2021-2025)

Figure 77. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

Figure 78. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

Figure 79. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

Figure 80. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

Figure 81. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Forecast (2021-2025)

Figure 82. Sales Channel: Direct Channel vs Indirect Channel

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz